drugset / Trial / NCT04149899
Safety and IOP-Lowering Effects of WB007
RandomizedParallel-groupTriple-blindTreatment
Summary
The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study. Part 1 was a 3-period dose escalation that evaluated 3 concentrations of WB007 ophthalmic solution following a single dose in one eye. Part 2 was a randomized, double-masked, parallel comparison that evaluated two concentrations of WB007 (selected based on Part 1 results) in both eyes compared with timolol 0.5% for 14 days.
Timeline
- Start
- 2019-11-14
- Primary completion
- 2021-01-31
- Completion
- 2022-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Timolol | Other / unclassified | 0.5 % | Other |
| Subject | WB007 | Unknown | 0.05 % | Other |
| Subject | WB007 | Unknown | 0.15 % | Other |
| Subject | WB007 | Unknown | 0.4 % | Other |